Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Endogenous glucose production is inhibited by the adipose-derived protein Acrp30
Terry P. Combs, … , Philipp E. Scherer, Luciano Rossetti
Terry P. Combs, … , Philipp E. Scherer, Luciano Rossetti
Published December 15, 2001
Citation Information: J Clin Invest. 2001;108(12):1875-1881. https://doi.org/10.1172/JCI14120.
View: Text | PDF
Article

Endogenous glucose production is inhibited by the adipose-derived protein Acrp30

  • Text
  • PDF
Abstract

Intraperitoneal injection of purified recombinant Acrp30 lowers glucose levels in mice. To gain insight into the mechanism(s) of this hypoglycemic effect, purified recombinant Acrp30 was infused in conscious mice during a pancreatic euglycemic clamp. In the presence of physiological hyperinsulinemia, this treatment increased circulating Acrp30 levels by approximately twofold and stimulated glucose metabolism. The effect of Acrp30 on in vivo insulin action was completely accounted for by a 65% reduction in the rate of glucose production. Similarly, glucose flux through glucose-6-phosphatase (G6Pase) decreased with Acrp30, whereas the activity of the direct pathway of glucose-6-phosphate biosynthesis, an index of hepatic glucose phosphorylation, increased significantly. Acrp30 did not affect the rates of glucose uptake, glycolysis, or glycogen synthesis. These results indicate that an acute increase in circulating Acrp30 levels lowers hepatic glucose production without affecting peripheral glucose uptake. Hepatic expression of the gluconeogenic enzymes phosphoenolpyruvate carboxykinase and G6Pase mRNAs was reduced by more than 50% following Acrp30 infusion compared with vehicle infusion. Thus, a moderate rise in circulating levels of the adipose-derived protein Acrp30 inhibits both the expression of hepatic gluconeogenic enzymes and the rate of endogenous glucose production.

Authors

Terry P. Combs, Anders H. Berg, Silvana Obici, Philipp E. Scherer, Luciano Rossetti

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Total
Citations: 4 9 8 11 16 11 8 5 10 9 16 15 17 8 17 11 15 12 12 11 5 7 10 1 248
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2012 (8)

Title and authors Publication Year
The Metabolic Syndrome and Risk of Chronic Kidney Disease: Pathophysiology and Intervention Strategies
HA Laguardia, LL Hamm, J Chen
Journal of nutrition and metabolism 2012
Emerging role of AMP-activated protein kinase in endocrine control of metabolism in the liver
CM Hasenour, ED Berglund, DH Wasserman
Molecular and Cellular Endocrinology 2012
Adiponectin regulates expression of hepatic genes critical for glucose and lipid metabolism
Q Liu, B Yuan, KA Lo, HC Patterson, Y Sun, HF Lodish
Proceedings of the National Academy of Sciences 2012
Adiponectin: mechanistic insights and clinical implications
AT Turer, PE Scherer
Diabetologia 2012
Adipocytokine Levels in Genetically High Risk for Type 2 Diabetes in the Indian Population: A Cross-Sectional Study
KS Bose, SK Gupta, P Vyas
Experimental Diabetes Research 2012
Association between high-molecular-weight adiponectin and bone mineral density in hemodialysis patients
N Amemiya, S Otsubo, Y Iwasa, T Onuki, K Nitta
Clinical and Experimental Nephrology 2012
Enhanced Fatty Acid Flux Triggered by Adiponectin Overexpression
S Shetty, MA Ramos-Roman, YR Cho, J Brown, J Plutzky, ES Muise, JD Horton, PE Scherer, EJ Parks
Endocrinology 2012
Novel variations in the adiponectin gene (ADIPOQ) may affect distribution of oligomeric complexes
LC Kottyan, JG Woo, M Keddache, W Banach, NA Crimmins, LM Dolan, LJ Martin
SpringerPlus 2012

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts